Kyowa Kirin Co Ltd
TSE:4151
Kyowa Kirin Co Ltd
Operating Income
Kyowa Kirin Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kyowa Kirin Co Ltd
TSE:4151
|
Operating Income
¥90.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Operating Income
¥479.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
33%
|
CAGR 10-Years
13%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Operating Income
¥265.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
13%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Operating Income
¥416B
|
CAGR 3-Years
40%
|
CAGR 5-Years
19%
|
CAGR 10-Years
7%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Operating Income
¥542B
|
CAGR 3-Years
8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Operating Income
-¥13.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.
See Also
What is Kyowa Kirin Co Ltd's Operating Income?
Operating Income
90.8B
JPY
Based on the financial report for Dec 31, 2024, Kyowa Kirin Co Ltd's Operating Income amounts to 90.8B JPY.
What is Kyowa Kirin Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
10%
Over the last year, the Operating Income growth was -3%. The average annual Operating Income growth rates for Kyowa Kirin Co Ltd have been 14% over the past three years , 11% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet